Novavax Settles Vaccine Supply Agreement Dispute
Company Announcements

Novavax Settles Vaccine Supply Agreement Dispute

Novavax ( (NVAX) ) has issued an announcement.

Novavax, Inc. and the UK Health Security Agency have reached a settlement to terminate their SARS-COV-2 Vaccine Supply Agreement, resolving disputes and releasing both parties from claims. Under the agreement, Novavax will refund $123.8 million to the UK, with payments spread over three years. This settlement offers a structured financial resolution while maintaining transparency for investors and stakeholders.

For detailed information about NVAX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyElliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz
TipRanks Auto-Generated NewsdeskNovavax Resumes Phase 3 Vaccine Trials After FDA Hold
TheFlyNovavax reports Q3 EPS (76c), consensus (83c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App